The concept of analytical performance includes different parameters that must be considered in the context of ensuring the quality, safety, and efficacy of an IVD device before placing it on the market. One of these parameters is precision (repeatability and reproducibility) which is summarized as the agreement between different independent measurement results of a sample in a series of measurements or between different series of measurements. Our customer sought our expertise to meet predetermined accuracy requirements on 26 parameters in the areas of bacterial infectious diseases, prenatal screening, oncology, and endocrinology to obtain CE marking for this instrument.

Discover the whole story in the case study below

The ability of developing high-parameter assays allows for a deeper characterization of patients’ immune subsets with limited sample availability. Spectral flow cytometry is used to assess high-parameter immune profiling in global clinical trials. To date, there are no specific guidelines for Performance Qualification (PQ) of spectral flow cytometers. Here, we describe an in-house developed workflow for performing PQ of a Cytek® Aurora instrument in a clinical laboratory.

As flow cytometry is one of the go-to methods for fast and in-depth monitoring of immune cell populations at single cell level, clinical laboratories are observing an increase in assay complexity and number of samples to process. To scale up our operations in a qualitative and efficient manner, several aspects of the laboratory design were improved and are discussed below.

Since 1992, Cerba Research/Healthcare has pioneered the art of human genetic testing, Cerba Healthcare builds the start of the art in human genetic testing by being the first laboratory in Europe to introduce Genetic testing.

Thanks to this experience, we are able to collaborate with the life science community to provide the most suitable genomic service and enhance the power of your genetic material.

Cerba Research can work with you to select the most suitable platform and assay to reach your project expectations.

Discover all our capabilities in our latest Genomics Brochure

Welcome to our immune repertoire sequencing white paper page! We provide advanced solutions to study the diversity and specificity of immune cells in your clinical trial samples, using cutting-edge sequencing technologies and bioinformatic tools.

By analyzing the RNA sequences of the immune receptors (i.e., B-cell or T-cell receptors), we can identify and quantify the different types of immune cells present in your samples, as well as their clonal relationships and antigen recognition patterns. This information can be used to investigate immune responses to diseases, vaccines, tumors, or environmental stimuli, and to develop personalized therapies and diagnostics.

Our team of experts can guide you through the entire process, from sample preparation to data analysis and interpretation, and provide you with customized reports and visualizations.

Explore the power of immune repertoire sequencing and unlock the secrets of the immune system!

What you can find in the white papers:

• The TCR and BCR sequencing workflow
• Our standard report analysis
• Cerba Research end-to-end solution sequencing service
• Features and benefits of TCR and BCR profiling
• And more intriguing features

Complete the form below to download the white papers!

Being one of the leading technologies for cellular analysis, flow cytometry generates simultaneous high-throughput enumeration and individual cell characterization data. With the breakthrough of cellular immune therapies, such as CAR+ T, flow cytometry became a critical platform, not only for clinical laboratories, but also for drug developers and manufacturers.

Flow cytometry plays a crucial role in the production process of CAR+ T cells, where it is used for assessing transduction efficiency, purity, and characterization of the CAR+ T product before infusion. After manufacturing, when CAR+ T cells are infused into the patients, flow cytometry is used again in clinical laboratories to assess CAR+ T expansion, efficiency, and persistence and to monitor minimal residual disease (MRD).

In this e-book, Ans De Beuckelaer, Regional Head Flow Cytometry EU and Rowan Claeys, Clinical Biologist at Cerba Research, dive deeper into key elements of flow cytometry:

• The importance of flow cytometry in Car+T clinical research and its uses
• Key aspects in developing a CAR+ T trial
• The added value of flow cytometryin multiple myeloma, Minimal Residual Disease (MRD) assessments and multiple Myeloma phenotype
• Car+T-cell Therapy: patient treatment, targeted antigens and solutions for MRD assessments and multiple myeloma phenotype assessment.